Recent findings showed that the KRAS G12D mutation leads to aggressive phenotype of MPN through mediation of Sos1, suggesting the use of Sos1-oncogenic Kras interaction as new therapeutic targets [93]. The gene discussed is SOS1; the disease is myeloproliferative neoplasm.